MCID: CHR070
MIFTS: 46

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 37 15
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 73
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 55

Classifications:



External Ids:

Disease Ontology 12 DOID:5213
ICD10 33 G61.81
ICD9CM 35 357.81
MeSH 44 D020277
NCIt 50 C84636
SNOMED-CT 68 128209004 444728005
KEGG 37 H01527
UMLS 73 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to hereditary neuropathy with liability to pressure palsy and neuropathy, hereditary, with liability to pressure palsies. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are TGF-Beta Pathway and Allograft rejection. The drugs Rho(D) Immune Globulin and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, t cells and skin, and related phenotypes are cellular and homeostasis/metabolism

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 hereditary neuropathy with liability to pressure palsy 31.0 MPZ PMP22
2 neuropathy, hereditary, with liability to pressure palsies 30.9 MPZ PMP22
3 hereditary neuropathies 30.8 MPZ PMP22
4 chronic graft versus host disease 30.7 ALB IFNG
5 demyelinating polyneuropathy 30.6 ALB PMP22
6 neuritis 30.6 IFNG MPZ PMP22
7 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 IFNG IL17A
8 guillain-barre syndrome 30.3 ALB MPZ PMP22
9 inflammatory bowel disease 28.7 ALB IFNG IL17A STAT1
10 polyradiculoneuropathy 28.7 ALB IFNG IL17A MPZ PMP22 PRF1
11 multiple sclerosis 27.7 IFNB1 IFNG IL17A MPZ PRF1 STAT1
12 chronic inflammatory demyelinating polyneuropathy 12.0
13 lewis-sumner syndrome 11.6
14 chronic inflammatory demyelinating polyneuritis 11.3
15 x-linked charcot-marie-tooth disease 11.2
16 congenital hypomyelination neuropathy 10.7 MPZ PMP22
17 charcot-marie-tooth neuropathy type 1 10.7 MPZ PMP22
18 foot drop 10.7 MPZ PMP22
19 roussy-levy hereditary areflexic dystasia 10.7 MPZ PMP22
20 charcot-marie-tooth disease, demyelinating, type 1f 10.7 MPZ PMP22
21 charcot-marie-tooth disease, demyelinating, type 1c 10.7 MPZ PMP22
22 charcot-marie-tooth disease, demyelinating, type 1b 10.7 MPZ PMP22
23 charcot-marie-tooth disease, axonal, type 2b 10.7 MPZ PMP22
24 motor peripheral neuropathy 10.6 MPZ PMP22
25 charcot-marie-tooth disease, demyelinating, type 1a 10.6 MPZ PMP22
26 charcot-marie-tooth disease, demyelinating, type 1d 10.6 MPZ PMP22
27 gastrointestinal tuberculosis 10.5 ALB IFNG
28 pelizaeus-merzbacher disease 10.5 MPZ PMP22
29 charcot-marie-tooth disease and deafness 10.5 MPZ PMP22
30 trichosporonosis 10.5 IFNG IL17A
31 fascioliasis 10.5 ALB IFNG
32 tuberculous peritonitis 10.5 ALB IFNG
33 hypersplenism 10.5 ALB IFNG
34 hemorrhagic fever 10.5 ALB IFNG
35 myositis fibrosa 10.5 IFNG IL17A
36 hepatitis e 10.4 ALB IFNG
37 hypertrophic neuropathy of dejerine-sottas 10.4 MPZ PMP22
38 aspiration pneumonia 10.4 ALB IL17A
39 primary systemic mycosis 10.4 IFNG IL17A
40 mucinoses 10.4 IFNB1 IFNG
41 neuropathy 10.4
42 typhoid fever 10.4 ALB IFNG
43 paranasal sinus disease 10.4 IFNG IL17A
44 echinococcosis 10.3 IFNG IL17A
45 septicemic plague 10.3 IFNB1 IL17A
46 campylobacteriosis 10.3 IFNG STAT1
47 sensory peripheral neuropathy 10.3 MPZ PMP22
48 multifocal motor neuropathy 10.3
49 human t-cell leukemia virus type 2 10.3 IFNG STAT1
50 tropical spastic paraparesis 10.3 IFNG IL17A

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 PRF1 STAT1 IFNG ALB CXCR4 MPZ
2 homeostasis/metabolism MP:0005376 10.02 STAT1 ALB IL17A CXCR4 MPZ PMP22
3 hematopoietic system MP:0005397 9.95 STAT1 IL17A CXCR4 MPZ IFNB1 PRF1
4 endocrine/exocrine gland MP:0005379 9.91 STAT1 ALB IL17A CXCR4 PRF1 IFNG
5 immune system MP:0005387 9.87 STAT1 IL17A CXCR4 MPZ IFNB1 PRF1
6 mortality/aging MP:0010768 9.86 STAT1 ALB IL17A CXCR4 MPZ PMP22
7 digestive/alimentary MP:0005381 9.85 STAT1 IFNG ALB IL17A CXCR4
8 muscle MP:0005369 9.55 STAT1 IFNG ALB CXCR4 PMP22
9 neoplasm MP:0002006 9.43 STAT1 ALB CXCR4 IFNB1 PRF1 IFNG
10 nervous system MP:0003631 9.17 STAT1 CXCR4 MPZ PMP22 IFNB1 PRF1

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 glucocorticoids Phase 3
11 Fingolimod Hydrochloride Phase 3
12 Hormone Antagonists Phase 3,Phase 2
13 Hormones Phase 3,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
15 Immunoglobulin G Phase 3,Not Applicable
16 Immunosuppressive Agents Phase 3,Phase 2
17 Anti-Inflammatory Agents Phase 3
18 Antineoplastic Agents, Hormonal Phase 3
19 Pharmaceutical Solutions Phase 3,Phase 2
20
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22 interferons Phase 2
23 Adjuvants, Immunologic Phase 2
24 Micronutrients Phase 2
25 Thioctic Acid Phase 2
26 Trace Elements Phase 2
27 Vitamin B Complex Phase 2
28 Vitamins Phase 2
29 Anti-Infective Agents Phase 2
30 Interferon-beta Phase 2
31 Antioxidants Phase 2
32 Protective Agents Phase 2
33 Antirheumatic Agents Phase 2
34 Antiviral Agents Phase 2
35 Folate Nutraceutical Phase 2
36 Alpha-lipoic Acid Nutraceutical Phase 2
37 Vitamin B9 Nutraceutical Phase 2
38
Infliximab Approved 170277-31-3
39 Gastrointestinal Agents
40 Dermatologic Agents

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
7 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
8 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
9 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
10 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
11 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
15 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
16 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
17 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
18 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
19 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
21 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
22 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
23 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
24 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
25 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
26 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
27 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
28 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
29 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
30 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
31 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
32 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
33 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
34 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
35 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
36 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
37 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
38 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
39 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
40 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
41 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
42 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
43 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
44 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890 Not Applicable
45 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

41
Spinal Cord, T Cells, Skin, Brain, Tongue, Nk Cells, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 332)
# Title Authors Year
1
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin. ( 29554579 )
2018
2
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>Ar</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. ( 29764262 )
2018
3
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
4
Pyrexia-associated Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. ( 29709940 )
2018
5
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. ( 29603842 )
2018
6
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
7
Risk factors for osteoporosis in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29896772 )
2018
8
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
9
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 29866282 )
2018
10
Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique. ( 29926221 )
2018
11
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
12
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
13
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
14
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
15
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
16
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
17
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
18
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
19
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
20
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
21
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
22
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
23
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
24
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
25
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
26
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
27
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
28
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
29
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
30
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
31
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. ( 27241239 )
2016
32
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
33
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
34
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
35
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. ( 27438336 )
2016
36
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
37
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. ( 27313890 )
2016
38
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. ( 27380808 )
2016
39
Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27211560 )
2016
40
A case of a 17-year-old male with neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. ( 27580761 )
2016
41
Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. ( 27838091 )
2016
42
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. ( 27580763 )
2016
43
Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. ( 27230584 )
2016
44
A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon I+-2a in a patient with chronic hepatitis B virus infection. ( 27680223 )
2016
45
IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. ( 27852440 )
2016
46
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. ( 26873805 )
2016
47
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. ( 27175635 )
2016
48
Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)? ( 26750580 )
2016
49
Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand. ( 27113227 )
2016
50
The frequencies of Killer immunoglobulin-like receptors and their HLA ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in Guillian Barre syndrome but differ from those of controls, suggesting a role for NK cells in pathogenesis. ( 26198918 )
2015

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 CXCR4 IFNB1 IFNG IL17A STAT1
2
Show member pathways
12.29 CXCR4 IFNG IL17A PRF1 STAT1
3
Show member pathways
12.25 IFNB1 IFNG STAT1
4
Show member pathways
12.23 IFNB1 IFNG PRF1
5
Show member pathways
12.16 IFNG IL17A STAT1
6
Show member pathways
12.15 IFNB1 IFNG IL17A STAT1
7 12.14 CXCR4 IFNG IL17A STAT1
8
Show member pathways
11.98 IFNB1 IFNG STAT1
9
Show member pathways
11.93 IFNG IL17A STAT1
10 11.89 IFNB1 IFNG STAT1
11
Show member pathways
11.85 IFNB1 IFNG STAT1
12
Show member pathways
11.8 IFNB1 IFNG STAT1
13 11.65 IFNB1 IFNG STAT1
14 11.05 IFNG IL17A
15 11.01 IFNB1 IFNG
16
Show member pathways
10.99 IFNG PRF1
17 10.96 IFNG PRF1
18 10.87 CXCR4 IFNB1 IFNG STAT1
19 10.7 IFNB1 IFNG STAT1

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.78 CXCR4 IFNG IL17A PRF1
2 cytokine-mediated signaling pathway GO:0019221 9.71 IFNB1 IL17A STAT1
3 cellular response to cytokine stimulus GO:0071345 9.52 CXCR4 STAT1
4 myelination GO:0042552 9.51 MPZ PMP22
5 cell death GO:0008219 9.49 IL17A PMP22
6 regulation of type I interferon-mediated signaling pathway GO:0060338 9.46 IFNB1 STAT1
7 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNB1 IFNG
8 response to virus GO:0009615 9.43 CXCR4 IFNB1 IFNG
9 positive regulation of osteoclast differentiation GO:0045672 9.4 IFNG IL17A
10 cellular response to interferon-beta GO:0035458 9.37 IFNB1 STAT1
11 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.32 IFNG STAT1
12 positive regulation of interleukin-23 production GO:0032747 9.16 IFNG IL17A
13 positive regulation of killing of cells of other organism GO:0051712 8.96 IFNG PRF1
14 defense response to virus GO:0051607 8.92 IFNB1 IFNG PRF1 STAT1

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 IFNB1 IFNG IL17A

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....